Adding an anti-inflammatory drug to anti-PD1 checkpoint inhibitor immunotherapy has shown great promise as a new strategy against advanced lung cancer, based on results from a small clinical trial led by investigators at the Abramson Family Cancer Center at the University of Pennsylvania Perelman School of Medicine.
Pα+ Psychedelic Patent Analysis (October 2023) – Psychedelic Alpha
While national phase entries for Compass’s WO2023114097 PCT are not due until June 2024 (30 months from the priority date), all claims relating to co-use
November 24, 2023